Nordic Nanovector
Kjelsåsveien 168 B
Oslo
0884
Tel: 47-22-18-33-01
Fax: 47-22-58-00-07
Website: http://www.nordicnanovector.no/
Email: mail@nordicnanovector.no
343 articles about Nordic Nanovector
-
Nordic Nanovector To Present At DNB Markets 5th Annual Health Care Conference Today
12/11/2014
-
Nordic Nanovector Patent Granted In Japan
12/10/2014
-
Nordic Nanovector Presented Phase I Study Data Reporting Promising Clinical Activity In Patients With Relapsed Non-Hodgkin Lymphoma At American Society of Hematology
12/8/2014
-
Nordic Nanovector To Present Clinical Data From Phase I/II Trial On Betalutin At Upcoming American Society of Hematology Meeting
12/3/2014
-
Nordic Nanovector And Affibody Collaborate On Advanced Radio-Immunotherapies Program For Multiple Myeloma
12/1/2014
-
Nordic Nanovector And Affibody Collaborate On New Advanced Radio-Immunotherapies Program For Multiple Myeloma
11/26/2014
-
Nordic Nanovector: Extraordinary General Meeting On 12 November 2014
11/4/2014
-
Nordic Nanovector Strengthens Management Team To Prepare For Its Next Phase
11/3/2014
-
Nordic Nanovector – Registered Share Capital Increase
10/28/2014
-
Nordic Nanovector: Issuance Of Shares To HealthCap VI L.P
10/24/2014
-
Nordic Nanovector: Registered Share Capital Increase
9/22/2014
-
Nordic Nanovector: Final Result Of The Subsequent Offering
9/16/2014
-
Nordic Nanovector – Preliminary Result Of The Subsequent Offering
9/15/2014
-
Nordic Nanovector – Approved Prospectus
8/29/2014
-
Nordic Nanovector: The Board Appoints Mr. Luigi Costa As New CEO
8/26/2014
-
Nordic Nanovector: Second Quarter Report 2014
8/26/2014
-
Extraordinary General Meeting Held In Nordic Nanovector
6/27/2014
-
Nordic Nanovector Intends To Undertake Private Placement Of NOK 150 Million
6/6/2014
-
Nordic Nanovector: Betalutin™ Granted Orphan-Drug Designation In The USA
5/20/2014
-
Nordic Nanovector: Annual General Meeting Held Today
5/14/2014